Dominic Eisinger of Rules-Based Medicine discusses an easy, reliable and cost-effective solution to immune system monitoring in clinical trials.
The issues around IP protection are often lost in the excitement around the scientific benefit of ELNs and deserve consideration in themselves. By Amphora Research Systems
Project teams have been drawing up lists of requirements since the dawn of time, and since that first list the fate of a project has to a great extent been sealed the moment the requirements have been finalized.
Today, more than ever before, biopharma companies are coming under pressure to demonstrate the value of their products in meaningful terms to varied stakeholders and audiences. By Quintiles
Robert Willis from Eurofins Medinet gives an overview of developments at the company.